|1.||Loganzo, Frank: 6 articles (05/2005 - 04/2003)|
|2.||Andersen, Raymond J: 4 articles (08/2009 - 04/2003)|
|3.||Greenberger, Lee M: 4 articles (05/2005 - 04/2003)|
|4.||Zask, Arie: 4 articles (05/2005 - 04/2003)|
|5.||Gleave, Martin E: 3 articles (08/2009 - 03/2008)|
|6.||Hadaschik, Boris A: 3 articles (08/2009 - 03/2008)|
|7.||Hari, Malathi: 3 articles (05/2005 - 04/2003)|
|8.||Ayral-Kaloustian, Semiramis: 3 articles (05/2005 - 04/2003)|
|9.||Musto, Sylvia: 3 articles (05/2005 - 04/2003)|
|10.||Annable, Tami: 3 articles (11/2004 - 04/2003)|
08/01/2009 - "Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer."
08/01/2009 - "In this study, we show promising efficacy of intravesical combination treatment using antisense oligonucleotides targeting heat shock protein-27 (Hsp27; OGX427) with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. "
03/01/2008 - "Mice with established KU-7-luc tumors were given HTI-286 or MMC intravesically twice a week for 2 h. "
11/14/2006 - "HTI-286 is currently undergoing clinical evaluation in cancer patients."
11/25/2003 - "HTI-286 inhibits the proliferation of tumor cells during mitosis. "
05/15/2008 - "Invivo, HTI-286 significantly inhibited growth of PC-3 and LNCaP xenografts and retained potency in PC-3dR tumors. "
11/14/2006 - "Moreover, intravenous administration of HTI-286 significantly inhibited tumor growth in vivo (rat allograft model). "
|3.||Urinary Bladder Neoplasms (Bladder Cancer)
03/01/2008 - "These findings provide preclinical proof-of-principle for HTI-286 as an intravesical therapy for nonmuscle-invasive bladder cancer and warrant further evaluation of efficacy and safety in early-phase clinical trials."
03/01/2008 - "In this study, we evaluate the inhibitory effects of HTI-286 on human bladder cancer growth, both in vitro and as an intravesical agent in an orthotopic murine model. "
08/01/2009 - "Then, four bladder cancer cell lines were screened for combination effects of OGX427 with HTI-286, and the molecular mechanisms underlying the synergic effect were analyzed. "
03/01/2008 - "Intravesical HTI-286 instillation therapy showed promising antitumor activity and minimal toxicity in an orthotopic mouse model of high-grade bladder cancer. "
08/01/2009 - "Our results suggest that OGX427 enhances cytotoxicity of HTI-286 through Akt inactivation and provide strong preclinical proof-of-principle for intravesical administration of OGX427 in combination with HTI-286 for high-grade bladder cancer."
11/09/2004 - "The basis of resistance to a synthetic analogue of hemiasterlin, HTI-286 (HTI), was examined in cell populations derived from ovarian carcinoma (A2780/1A9) cells selected in HTI-286. "
04/15/2003 - "In athymic mice implanted with human tumor xenografts, HTI-286 administered i.v. in saline inhibited the growth of numerous human tumors derived from carcinoma of the skin, breast, prostate, brain, and colon. "
|5.||Prostatic Neoplasms (Prostate Cancer)
05/15/2008 - "Androgen-dependent and androgen-independent prostate cancer cell lines including a docetaxel-refractory PC-3 subline (PC-3dR) were treated with HTI-286. "
05/15/2008 - "Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin."
05/15/2008 - "In conclusion, HTI-286 showed strong antitumor activity both in androgen-dependent and androgen- independent tumors and may be a promising agent in second- line treatment strategies for patients suffering from docetaxel- refractory prostate cancer."
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Homologous Transplantation (Allograft)
|3.||Drug Therapy (Chemotherapy)